Efficacy Results from IYUZEH™
IOP-lowering efficacy from latanoprost, without preservatives
*In the US clinical trial, the mean IOP baseline was 18.8 mmHg for IYUZEH (n=165) and 19.2 mmHg for XALATAN® (n=169) compared with 24.1 mmHg for IYUZEH (n=189) and 24 mmHg for XALATAN (n=164) in the European clinical trial, accounting for the smaller yet still clinically meaningful IOP-lowering effect.1-4
XALATAN is a registered trademark of Pfizer PFE Holdings 4 LLC, a Viatris Company.
IYUZEH has been demonstrated effective in 7 studies with a total of 3746 patients across the globe.1,5
Hear what your colleagues are saying about IYUZEH
In the study, there was a very important differentiating factor that most new agents don’t have–the bar. And the bar in this study was branded XALATAN. Most of the Phase III trials for approval of medicines in the US for glaucoma and ocular hypertension, the comparator is beta blockers. And so, for IYUZEH, in its pivotal studies, to go against XALATAN, that’s a pretty high bar.
Jason M. Bacharach, MD
Dr. Bacharach is a paid consultant of Thea Pharma Inc.
Visit our Video Library to Hear Why Eye Care Professionals are Choosing IYUZEH
Things your patients may not say, but could be thinking
Eileen has been on a latanoprost generic for a few years and has done her homework on the different ingredients in ophthalmic solutions that lower IOP. While she’s really interested in a treatment without benzalkonium chloride (BAK), she doesn’t want to risk any increase in IOP.
Eileen heard about IYUZEH – the first and only preservative-free latanoprost. With the help of her eye care professional, she switched and is very satisfied with her treatment.
†Patient portrayal. Not an actual patient.
